

Javier Cortes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1255878/javier-cortes-publications-by-year.pdf>

Version: 2023-09-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

243
papers

16,735
citations

54
h-index

127
g-index

263
ext. papers

21,663
ext. citations

11
avg, IF

6.27
L-index

#	Paper	IF	Citations
243	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 556-567	59.2	29
242	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221083956	5.4	4
241	Immunotherapy for early triple negative breast cancer: research agenda for the next decade.. <i>Npj Breast Cancer</i> , 2022 , 8, 23	7.8	7
240	Gene signatures in patients with early breast cancer and relapse despite pathologic complete response.. <i>Npj Breast Cancer</i> , 2022 , 8, 42	7.8	1
239	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 1143-1154	59.2	25
238	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200338	2.2	7
237	CDK4/6 inhibitors in breast cancer: spotting the difference. <i>Nature Medicine</i> , 2021 , 27, 1868-1869	50.5	1
236	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2021 ,	220.7	10
235	Epstein-Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report. <i>Frontiers in Immunology</i> , 2021 , 12, 761798	8.4	0
234	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021 , 7, 145	7.8	0
233	Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211059587	5.4	1
232	Targeting brain metastases in breast cancer.. <i>Cancer Treatment Reviews</i> , 2021 , 103, 102324	14.4	6
231	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. <i>Cancers</i> , 2021 , 13,	6.6	1
230	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021 , 21, 181-190.e2	3	7
229	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2021 , 124, 1581-1591	8.7	4
228	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 499-511	21.7	68
227	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021 , 384, 1529-1541	59.2	108

226	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 811-824	5.4	2
225	Nobody dares stopping clinical research, not even COVID-19. <i>Npj Breast Cancer</i> , 2021 , 7, 39	7.8	
224	Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial. <i>European Journal of Cancer</i> , 2021 , 148, 382-394	7.5	5
223	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. <i>Npj Breast Cancer</i> , 2021 , 7, 57	7.8	3
222	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. <i>European Journal of Cancer</i> , 2021 , 148, 134-145	7.5	3
221	Chemotherapy de-escalation using an F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 858-871	21.7	7
220	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021 , 7, 73	7.8	2
219	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1875, 188487	11.2	9
218	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1143-1155	9.7	8
217	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021 , 27, 3116-3125	12.9	3
216	Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply. <i>Lancet, The</i> , 2021 , 398, 24-25	40	1
215	I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment. <i>Cancer Cell</i> , 2021 , 39, 902-904	24.3	
214	Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3541-3545	2.2	2
213	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
212	Atezolizumab in the treatment of metastatic triple-negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 981-989	5.4	9
211	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. <i>European Journal of Cancer</i> , 2020 , 135, 62-65	7.5	26
210	High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study. <i>Breast Cancer</i> , 2020 , 27, 706-715	3.4	15
209	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 810-821	59.2	599

208	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 105-124	220.7	63
207	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020 , 11, 385	17.4	36
206	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1951-1962	2.2	74
205	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR, HER2 Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6417-6428	12.9	5
204	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1000-1000	2.2	92
203	PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1007-1007	2.2	24
202	Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 503-503	2.2	18
201	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1096-1104	7.3	13
200	Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 423-433	2.2	123
199	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 610-621	59.2	536
198	Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 35-45	12.9	14
197	Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis. <i>Breast Journal</i> , 2020 , 26, 1347-1351	1.2	5
196	Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients. <i>Cancer Treatment Reviews</i> , 2020 , 83, 101944	14.4	3
195	Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	10
194	Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. <i>Breast Cancer Research</i> , 2020 , 22, 124	8.3	7
193	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , 2020 , 396, 1817-1828	40	306
192	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020 , 12,	6.6	2
191	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology, The</i> , 2020 , 21, 1455-1464	21.7	20

190	Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges. <i>BioDrugs</i> , 2020 , 34, 611-623	7.9	21
189	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020 , 38, 3987-3998	2.2	152
188	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , 2020 , 80, 5427-5434	10.1	32
187	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 5820-5829	12.9	17
186	CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge. <i>Cancers</i> , 2020 , 12,	6.6	6
185	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 46-54	9.7	48
184	Lucitanib for the Treatment of HR/HER2 Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020 , 26, 354-363	12.9	19
183	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1556-1564	13.4	38
182	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. <i>European Journal of Cancer</i> , 2019 , 120, 1-9	7.5	27
181	The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. <i>Cell Reports</i> , 2019 , 27, 2690-2708	10.6	198
180	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2019 , 15, 1951-1961	3.6	33
179	The Allele of rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin. <i>Frontiers in Oncology</i> , 2019 , 9, 193	5.3	10
178	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 69-77	9.7	40
177	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019 , 25, 6598-6605	12.9	11
176	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 571-571	2.2	4
175	XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1951-1961	2.2	3
174	KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS601-TPS601	2.2	4
173	Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. <i>Current Breast Cancer Reports</i> , 2019 , 11, 248-258	0.8	1

172	Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. <i>Clinical Breast Cancer</i> , 2019 , 19, 105-112	3	7
171	Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. <i>Genome Medicine</i> , 2019 , 11, 1	14.4	32
170	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. <i>Lancet Oncology, The</i> , 2018 , 19, 812-824	21.7	70
169	Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. <i>Clinical Cancer Research</i> , 2018 , 24, 3348-3357	12.9	15
168	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. <i>Investigational New Drugs</i> , 2018 , 36, 848-859	4.3	31
167	Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2018 , 63, 144-155	14.4	13
166	Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis. <i>Clinical Breast Cancer</i> , 2018 , 18, e919-e926	3	4
165	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018 , 24, 5820-5829	12.9	47
164	Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 6367-6382	12.9	27
163	SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS1101-TPS1101	2.2	4
162	Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS1106-TPS1106	2.2	1
161	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS602-TPS602	2.2	23
160	Phase III study of tselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. <i>Journal of Clinical Oncology</i> , 2018 , 36, LBA1006-LBA1006	2.2	99
159	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS618-TPS618	2.2	6
158	Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. <i>European Journal of Cancer</i> , 2018 , 89, 27-35	7.5	101
157	Breast cancer in 2017: Spurring science, marking progress, and influencing history. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 79-80	19.4	3
156	Reply to K.S. Shohdy et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2458-2459	2.2	
155	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018 , JCO2017748392	2.2	35

154	A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. <i>Oncotarget</i> , 2018 , 9, 35687-35704	3.3	34
153	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018 , 9, 20617-20630	3.3	26
152	p95HER2-T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	40
151	Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. <i>Cancer Treatment Reviews</i> , 2018 , 70, 190-198	14.4	37
150	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. <i>European Journal of Cancer</i> , 2018 , 103, 147-154	7.5	38
149	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017 , 23, 649-657	12.9	75
148	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 545-554	21.7	175
147	Role of total tumour load of sentinel lymph node on survival in early breast cancer patients. <i>Breast</i> , 2017 , 33, 8-13	3.6	20
146	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5218-5224	12.9	327
145	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 904-916	21.7	330
144	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 329-341	4.4	31
143	Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. <i>European Journal of Cancer</i> , 2017 , 76, 205-215	7.5	11
142	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 163, 535-544	4.4	14
141	Advances in the management of HER2-positive early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 119, 113-122	7	31
140	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017 , 1868, 527-537	11.2	29
139	The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. <i>Cancer Treatment Reviews</i> , 2017 , 61, 53-60	14.4	31
138	The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group. <i>Npj Breast Cancer</i> , 2017 , 3, 23	7.8	5
137	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 601-609	4.4	16

136	F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 1432-1441	12.9	25
135	Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1089-1089	2.2	9
134	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. <i>Cell</i> , 2016 , 167, 260-274.e22	56.2	274
133	Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016 , 10, 77-84	2.2	31
132	Translating neoadjuvant therapy into survival benefits: one size does not fit all. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 566-79	19.4	28
131	High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. <i>Molecular Oncology</i> , 2016 , 10, 138-147	7.9	52
130	Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 530-530	2.2	4
129	Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 537-537	2.2	2
128	HER2-positive metastatic breast cancer: first-line treatment 2016 , 51-69		
127	Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 528-528	2.2	2
126	ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS619-TPS619	2.2	1
125	Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. <i>SpringerPlus</i> , 2016 , 5, 1033		5
124	Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3831-3837	3.1	21
123	Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases. <i>Cancer and Metastasis Reviews</i> , 2016 , 35, 323-32	9.6	9
122	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2016 , 76, 2301-13	10.1	344
121	Etirinotecan pegol for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 727-34	4	2
120	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <i>Science Translational Medicine</i> , 2015 , 7, 283ra51	17.5	204
119	Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. <i>Journal of Clinical Oncology</i> , 2015 , 33, 594-601	2.2	282

118	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. <i>Lancet Oncology, The, 2015, 16, 1700-10</i>	21.7	85
117	Influencing cancer treatment. <i>Lancet Oncology, The, 2015, 16, 1591-3</i>	21.7	2
116	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. <i>Trials, 2015, 16, 575</i>	2.8	20
115	Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology, The, 2015, 16, 1556-1568</i>	21.7	63
114	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. <i>Nature Communications, 2015, 6, 8839</i>	17.4	416
113	High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. <i>Clinical Cancer Research, 2015, 21, 569-76</i>	12.9	58
112	Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. <i>Molecular Oncology, 2015, 9, 1081-90</i>	7.9	25
111	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. <i>New England Journal of Medicine, 2015, 372, 724-34</i>	59.2	1242
110	Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician's Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.. <i>Journal of Clinical Oncology, 2015, 33, 1001-1001</i>	2.2	3
109	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology, 2015, 33, 1003-1003</i>	2.2	81
108	A randomized phase III study of vinflunine versus an alkylating agent of physician's choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid.. <i>Journal of Clinical Oncology, 2015, 33, 1031-1031</i>	2.2	6
107	HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology, 2015, 33, 605-605</i>	2.2	1
106	Survival in triple-negative breast cancer (TNBC): Evidence from the SEER database 2010-2011.. <i>Journal of Clinical Oncology, 2015, 33, e12075-e12075</i>	2.2	2
105	HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and trastuzumab.. <i>Journal of Clinical Oncology, 2015, 33, TPS1106-TPS1106</i>	2.2	2
104	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget, 2015, 6, 37269-80</i>	3.3	112
103	Impact of locoregional therapy among women 70 years or older with early stage hormone receptor positive breast cancer: A population based study.. <i>Journal of Clinical Oncology, 2015, 33, 573-573</i>	2.2	
102	Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).. <i>Journal of Clinical Oncology, 2015, 33, TPS1106-TPS1106</i>	2.2	
101	Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. <i>Journal of Clinical Oncology, 2014, 32, 3626-33</i>	2.2	96

100	A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. <i>Breast</i> , 2014 , 23, 656-62	3.6	36
99	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. <i>Molecular Oncology</i> , 2014 , 8, 150-8	7.9	34
98	New approach to cancer therapy based on a molecularly defined cancer classification. <i>Ca-A Cancer Journal for Clinicians</i> , 2014 , 64, 70-4	220.7	20
97	Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	132
96	Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3753-61	2.2	243
95	Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	30
94	Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 553-61	4.4	140
93	The Fibroblast Growth Factor Receptor: A New Potential Target for the Treatment of Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014 , 6, 51-58	0.8	2
92	Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients with HER2-positive MBC: MO28230 TRAX-HER2 phase 1 results.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 606-606	2.2	2
91	Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 631-631	2.2	1
90	Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 649-649 ²	2.2	1
89	FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS1134-TPS1134	2.2	1
88	tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS1146-TPS1146	2.2	2
87	A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS653-TPS653	2.2	
86	Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS665-TPS665	2.2	1
85	Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11105-11105	2.2	
84	Impact of marital status on prognostic outcome of women with breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 594-594	2.2	
83	Effect of age and tumor size on prognostic outcome of women with breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 592-592	2.2	

82	Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 137-137	2.2	
81	Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer. <i>Advances in Therapy</i> , 2013 , 30, 645-58	4.1	13
80	Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2. <i>International Journal of Cancer</i> , 2013 , 133, 2315-24	7.5	30
79	Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. <i>Clinical Cancer Research</i> , 2013 , 19, 1884-93	12.9	30
78	Bone metastases: Causes, consequences and therapeutic opportunities. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 254-6	1.6	5
77	Multidisciplinary approach to breast cancer diagnosed during pregnancy: maternal and neonatal outcomes. <i>Breast</i> , 2013 , 22, 515-9	3.6	15
76	Adjuvant bevacizumab: positive data from a negative trial. <i>Lancet Oncology, The</i> , 2013 , 14, 910-1	21.7	2
75	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2013 , 14, 461-71	21.7	687
74	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 377-89	19.4	146
73	Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. <i>Breast</i> , 2013 , 22, 19-23	3.6	21
72	Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens. <i>Anti-Cancer Drugs</i> , 2013 , 24, 975-9	2.4	
71	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. <i>Oncologist</i> , 2013 , 18, 257-64	5.7	107
70	Reply to A. Ocana et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1253-4	2.2	
69	Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. <i>PLoS ONE</i> , 2013 , 8, e66933	3.3	9
68	A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1049-1049	2.2	5
67	Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1050-1050	2.2	2
66	Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2561-2561	2.2	2
65	Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 517-517	2.2	3

64	Is the proportion of patients with synchronous stage IV breast cancer surviving > 2 years increasing over time?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 524-524	2.2	1
63	A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 555-555	2.2	4
62	The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS1136-TPS1136	2.2	1
61	HER2-Positive Metastatic Breast Cancer: First-Line Treatment 2013 , 43-60		
60	PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS665-TPS665	2.2	
59	Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS649-TPS649	2.2	
58	Quality of life (QoL) and content validity in objective tumor response.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1055-1055	2.2	
57	Final results of a phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 547-547	2.2	0
56	Incidence and characteristics of breast cancer following a diagnosis of ductal carcinoma in situ.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1131-1131	2.2	
55	Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. <i>Breast</i> , 2012 , 21, 272-5	3.6	13
54	Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?. <i>Breast</i> , 2012 , 21, 604-7	3.6	13
53	Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomes. <i>Clinical Breast Cancer</i> , 2012 , 12, 287-92	3	15
52	Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1594-600	2.2	189
51	PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. <i>Cancer Discovery</i> , 2012 , 2, 1036-47	24.4	418
50	Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2012 , 38, 143-51	14.4	31
49	Docetaxel combined with targeted therapies in metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2012 , 38, 387-96	14.4	10
48	Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. <i>European Journal of Cancer</i> , 2012 , 48, 475-81	7.5	21
47	Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 109-19	59.2	1752

46	Circulating tumour cells in early breast cancer. <i>Lancet Oncology, The</i> , 2012 , 13, e370; author reply e370	21.7	2
45	A roadmap for accelerated drug approval in breast cancer?. <i>Lancet Oncology, The</i> , 2012 , 13, 850-1	21.7	1
44	Potential clinical applications of halichondrins in breast cancer and other neoplasms. <i>Breast Cancer: Targets and Therapy</i> , 2012 , 4, 9-19	3.9	1
43	The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. <i>Cancer</i> , 2012 , 118, 2780-6	6.4	20
42	Beyond taxanes: the next generation of microtubule-targeting agents. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 821-30	4.4	40
41	Molecular pathways: targeting hsp90--who benefits and who does not. <i>Clinical Cancer Research</i> , 2012 , 18, 4508-13	12.9	52
40	Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. <i>Oncologist</i> , 2012 , 17, 631-44	5.7	25
39	Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. <i>Current Drug Metabolism</i> , 2012 , 13, 911-22	3.5	37
38	First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 921-9	2.2	212
37	Progress against solid tumors in danger: the metastatic breast cancer example. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3444-7	2.2	17
36	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 509-509	2.2	3
35	Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 597-597	2.2	7
34	Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 598-598	2.2	6
33	A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS652-TPS652	2.2	1
32	Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 619-619	2.2	
31	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 566-566	2.2	
30	Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10511-10511	2.2	
29	Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS1140-TPS1140	2.2	

28	Impact of surgery and radiation of the primary among women with de novo stage IV breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1032-1032	2.2	
27	Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer. <i>Future Oncology</i> , 2011 , 7, 355-64	3.6	3
26	HER2 and hormone receptor-positive breast cancer--blocking the right target. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 307-11	19.4	24
25	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. <i>Lancet, The</i> , 2011 , 377, 914-23	4.0	764
24	Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer. <i>OncoTargets and Therapy</i> , 2011 , 4, 185-92	4.4	8
23	Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2011 , 18, 268-75	2.8	19
22	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 3761-6	11.5	241
21	Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3239-47	2.2	711
20	Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. <i>Journal of Clinical Oncology</i> , 2010 , 28, 960-6	2.2	31
19	Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1131-7	2.2	135
18	Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1138-44	2.2	496
17	Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3922-8	2.2	177
16	Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain. <i>Clinical and Translational Oncology</i> , 2010 , 12, 692-700	3.6	14
15	Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2010 , 10, 160-3	3	94
14	Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth. <i>BMC Cancer</i> , 2010 , 10, 265	4.8	22
13	Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. <i>Clinical Cancer Research</i> , 2009 , 15, 307-14	12.9	57
12	Risk of venous thromboembolism with bevacizumab in cancer patients. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 1434-5; author reply 1435-6	27.4	6
11	How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5492-4	2.2	16

10	Prognostic and predictive factors and genetic analysis of early breast cancer. <i>Clinical and Translational Oncology</i> , 2009 , 11, 634-42	3.6	6
9	Hepatic resection for liver metastases as part of the "oncosurgical" treatment of metastatic breast cancer. <i>Annals of Surgical Oncology</i> , 2008 , 15, 2804-10	3.1	67
8	Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 628-38	9.7	624
7	Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2007 , 14, 221-32	5.7	121
6	Targeting the microtubules in breast cancer beyond taxanes: the epothilones. <i>Oncologist</i> , 2007 , 12, 271-80	3.7	121
5	Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 64, 1122-8	4	60
4	Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 61, 1378-84	4	12
3	Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 299-303	2.7	2
2	Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. <i>Oncology</i> , 2003 , 64, 28-35	3.6	106
1	Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. <i>Oncology</i> , 2002 , 63, 254-65	3.6	15